Bimekizumabe em pacientes com artrite psoriática ativa e resposta inadequada anterior ou intolerância a inibidores do fator de necrose tumoral: Um estudo de fase 3, randomizado, duplo-cego, controlado com placebo (BE COMPLETE)
Lancet. 2023 doi: 10.1016/S0140-6736(22)02303-0
This study showed rapid and clinically meaningful improvements with bimekizumab treatment in patients experiencing active PsA and showing an inadequate response or intolerance to TNFα inhibitors. Its chief aim was to evaluate the efficacy and safety of bimekizumab in patients with an inadequate response or intolerance to TNFα inhibitors.
Keywords:
